Have a personal or library account? Click to login
Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia Cover

Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia

Forum of Clinical Oncology
Volume 10 (2019): Issue 2 (December 2019)
By: Amrallah A. Mohammed,  Hanna M. Ibrahim,  Hanna A. Atwa,  Ayman Elshentenawy and  Amira Elwan  
Open Access
|Apr 2020

Figures & Tables

Figure 1

Staining of cyclin D1 and DJ-1 in benign prostatic hyperplasia and prostatic adenocarcinoma: A)Benign prostatic hyperplasia showing negative cyclin D1 staining (ABC × 400)B)High grade prostatic adenocarcinoma showing strong Cyclin D1 staining (ABC × 200)C)Benign prostatic hyperplasia showing faint DJ1 intensity (ABC × 100)D)High grade Prostatic adenocarcinoma with strong DJ1 intensity (ABC × 400)
Staining of cyclin D1 and DJ-1 in benign prostatic hyperplasia and prostatic adenocarcinoma: A)Benign prostatic hyperplasia showing negative cyclin D1 staining (ABC × 400)B)High grade prostatic adenocarcinoma showing strong Cyclin D1 staining (ABC × 200)C)Benign prostatic hyperplasia showing faint DJ1 intensity (ABC × 100)D)High grade Prostatic adenocarcinoma with strong DJ1 intensity (ABC × 400)

Figure 2

Bar chart shows percent of relapse among different studied subpopulation of prostatic carcinoma patients.
Bar chart shows percent of relapse among different studied subpopulation of prostatic carcinoma patients.

Figure 3

Bar chart shows percent of hormone refractory relapse among different studied subpopulation of prostatic carcinoma patients
Bar chart shows percent of hormone refractory relapse among different studied subpopulation of prostatic carcinoma patients

Figure 4

ROC curve for sensitivity and specificity of cyclin D1 in prediction of prostatic carcinoma
ROC curve for sensitivity and specificity of cyclin D1 in prediction of prostatic carcinoma

Figure 5

ROC curve for sensitivity and specificity of DJ-1 in prediction of prostatic carcinoma
ROC curve for sensitivity and specificity of DJ-1 in prediction of prostatic carcinoma

Comparison between PC and BPH as regard cyclin D1 and DJ-1 (staining and overexpression)

Prostatic Carcinoma (N=40)Prostatic Hyperplasia (N=40)p-value‡
No.(%)No.(%)
Cyclin D1 extent
Negative2(5%)39(97.5%)< 0.001
Positive38(95%)1(2.5%)
DJ1 extent
Negative6(15%)39(97.5%)< 0.001
Positive34(85%)1(2.5%)
Cyclin D1 extent /DJ1 extent
Negative/Negative2(5%)38(95%)< 0.001
Negative/Positive0(0%)1(2.5%)
Positive/Negative4(10%)1(2.5%)
Positive/Positive34(85%)0(0%)
Cyclin D1 intensity
02(5%)39(97.5%)< 0.001
15(12.5%)1(2.5%)
216(40%)0(0%)
317(42.5%)0(0%)
DJ1 intensity
06(15%)39(97.5%)< 0.001
14(10%)0(0%)
214(35%)1(2.5%)
316(40%)0(0%)
Cyclin D1 intensity/DJ1 intensity
0/02(5%)38(95%)< 0.001
0/10(0%)0(0%)
0/20(0%)1(2.5%)
1/01(2.5%)1(2.5%)
1/14(10%)0(0%)
1/20(0%)0(0%)
2/03(7.5%)0(0%)
2/10(0%)0(0%)
2/210(25%)0(0%)
2/33(7.5%)0(0%)
3/24(10%)0(0%)
3/313(32.5%)0(0%)
Cyclin D1 overexpression
Negative23(57.5%)
Positive17(42.5%)
DJ-1 overexpression
Negative21(52.5%)
Positive19(47.5%)

Clinicopathological features and outcome of 40 patients with prostatic carcinoma_

CharacteristicsProstatic Carcinoma (N=40)CharacteristicsProstatic Carcinoma (N=40)
No.%No.%
Gleason scoreRelapse
< 7717.5%Absent1640%
= 71127.5%Present2460%
➢72255%
TDistant metastasis
T1512.5%Absent1640%
T21435%Present2460%
T32152.5%
StageHormone Refractory Relapse(N=24)
Stage I37.5%Absent729.2%
Stage IIa615%Present1770.8%
Stage IIb1025%
Stage III2125%

Relation between cyclin D1 and DJ-1 (staining and overexpression), clinicopathological parameters and relapse in 40 PC patients

Prostatic Carcinoma (N=40)Relapsep-value
Absent (N=16)Present (N=24)
No.(%)No.(%)No.(%)
Gleason score
< 77(17.5%)7(100%)0(0%)< 0.001§
= 711(27.5%)9(81.8%)2(18.2%)
➢722(55%)0(0%)22(100%)
T
T15(12.5%)5(100%)0(0%)< 0.001§
T214(35%)11(78.6%)3(21.4%)
T321(52.5%)0(0%)21(100%)
Stage
Stage I3(7.5%)3(100%)0(0%)< 0.001§
Stage IIa6(15%)6(100%)0(0%)
Stage IIb10(25%)7(70%)3(30%)
Stage III21(25%)0(0%)21(100%)
Cyclin D1 extent
Negative2(5%)2(100%)0(0%)0.154‡
Positive38(95%)14(36.8%)24(63.2%)
DJ1 extent
Negative6(15%)6(100%)0(0%)0.002‡
Positive34(85%)10(29.4%)24(70.6%)
Cyclin D1 extent /DJ1 extent
−ve/−ve2(5%)2(100%)0(0%)0.003§
+ve/−ve4(10%)4(100%)0(0%)
+ve/+ve34(85%)10(29.4%)24(70.6%)
Cyclin D1 intensity
02(5%)2(100%)0(0%)0.002§
15(12.5%)5(100%)0(0%)
216(40%)5(31.3%)11(68.8%)
317(42.5%)4(23.5%)13(76.5%)
DJ1 intensity
06(15%)6(100%)0(0%)< 0.001§
14(10%)4(100%)0(0%)
214(35%)6(42.9%)8(57.1%)
316(40%)0(0%)16(100%)
Cyclin D1 intensity/DJ1 intensity
0/02(5%)2(100%)0(0%)< 0.001§
1/01(2.5%)1(100%)0(0%)
1/14(10%)4(100%)0(0%)
2/03(7.5%)3(100%)0(0%)
2/210(25%)2(20%)8(80%)
2/33(7.5%)0(0%)3(100%)
3/24(10%)4(100%)0(0%)
3/313(32.5%)0(0%)13(100%)
Cyclin D1 overexpression
Negative23(57.5%)16(69.6%)7(30.4%)< 0.001‡
Positive17(42.5%)0(0%)17(100%)
DJ1 overexpression
Negative21(52.5%)16(76.2%)5(23.8%)< 0.001‡
Positive19(47.5%)0(0%)19(100%)

Relation between cyclin D1 and DJ-1 (staining and overexpression), clinicopathological parameters and hormone response in 40 PC patients

Prostatic Carcinoma (N=24)Hormone Refractoryp-value
Absent (N=7)Present (N=17)
No.(%)No.(%)No.(%)
Gleason score
= 72(8.3%)0(0%)2(100%)1.000‡
➢722(91.7%)7(31.8%)15(68.2%)
T
T23(12.5%)1(33.3%)2(66.7%)1.000‡
T321(87.5%)6(28.6%)15(71.4%)
Stage
Stage IIb3(12.5%)1(33.3%)2(66.7%)1.000‡
Stage III21(87.5%)6(28.6%)15(71.4%)
Cyclin D1 extent
Positive24(100%)7(29.2%)17(70.8%)---
DJ1 extent
Positive24(100%)7(29.2%)17(70.8%)---
Cyclin D1 extent /DJ1 extent
+ve/+ve24(100%)7(29.2%)17(70.8%)---
Cyclin D1 intensity
211(45.8%)0(0%)11(100%)0.006‡
313(54.2%)7(53.8%)6(46.2%)
DJ1 intensity
28(33.3%)0(0%)8(100%)0.054‡
316(66.7%)7(43.8%)9(56.3%)
Cyclin D1 intensity/DJ1 intensity
2/28(33.3%)0(0%)8(100%)0.006§
2/33(12.5%)0(0%)3(100%)
3/313(54.2%)7(53.8%)6(46.2%)
Cyclin D1 overexpression
Negative7(29.2%)7(100%)0(0%)<0.001‡
Positive17(70.8%)0(0%)17(100%)
DJ1 overexpression
Negative5(20.8%)5(100%)0(0%)<0.001‡
Positive19(79.2%)2(10.5%)17(89.5%)
DOI: https://doi.org/10.2478/fco-2019-0005 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 15 - 25
Submitted on: Aug 3, 2018
Accepted on: Jul 21, 2019
Published on: Apr 5, 2020
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Prostate carcinoma,
benign prostatic hyperplasia,
cyclin D1,
DJ-1
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2020 Amrallah A. Mohammed, Hanna M. Ibrahim, Hanna A. Atwa, Ayman Elshentenawy, Amira Elwan, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 10 (2019): Issue 2 (December 2019)Next article